XBIT - XB2001 Phase I/II Trial Completion in Advanced Pancreatic Cancer
Jun 10, 2025, 4:00:00 AM UTC
Summary
XBiotech is expected to complete its Phase I/II clinical trial of XB2001, an anti-IL-1⍺ antibody, in combination with ONIVYDE and 5-FU/LV for advanced pancreatic cancer on June 10, 2025. The study, conducted in the US, evaluates safety, tolerability, and efficacy in approximately 69 patients. ONIVYDE (irinotecan liposome) and 5-FU/LV are standard chemotherapies for pancreatic cancer. XB2001 is being investigated as an adjunct to improve outcomes in metastatic disease.
Company
XBIOTECH INC (XBIT)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.xbiotech.comSimilar Events
Phase 2 Trial Completion: Combination Immunotherapy in Pancreatic Cancer (NCT04390399)
ImmunityBio is expected to complete its phase 2 clinical trial (NCT04390399) evaluating combination immunotherapy (aldoxorubicin HCl, N-803, and PD-L1 t-haNK) plus standard chemotherapy versus chemotherapy alone in patients with locally advanced or metastatic pancreatic cancer on October 31, 2025. The study, with 328 participants, aims to assess efficacy and safety across multiple treatment lines. Results may inform future development of novel immunotherapy regimens for pancreatic cancer.
trial completionXmAb20717 Phase II Trial Completion in Biliary Tract Cancer
A Phase II clinical trial evaluating XmAb20717, a bispecific antibody targeting PD-1 and CTLA-4, in patients with advanced biliary tract cancers intolerant to gemcitabine-based chemotherapy is expected to complete on December 2, 2026. The study, sponsored by Abramson Cancer Center at Penn Medicine, aims to assess the efficacy and safety of XmAb20717 in this patient population. XmAb20717 is an investigational immunotherapy developed by Xencor (XNCR) for solid tumors.
trial completionNC410 and FOLFIRINOX plus Nivolumab Clinical Trial Completion (Pancreatic Cancer)
A Phase 2 clinical trial evaluating the safety and novel toxicities of NC410 and FOLFIRINOX in combination with nivolumab, with or without ipilimumab, in patients with untreated metastatic pancreatic cancer is expected to complete on June 1, 2030. The study, sponsored by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, aims to enroll 20 participants. NC410 is an investigational immunotherapy targeting the immune checkpoint pathway, while FOLFIRINOX is a standard chemotherapy regimen for pancreatic cancer. Nivolumab and ipilimumab are immune checkpoint inhibitors.
trial completionPhase II Study Completion of Ivonescimab in Metastatic Colorectal Cancer
A Phase II clinical trial evaluating ivonescimab, an anti-PD-1/VEGF bispecific antibody, in patients with previously treated metastatic colorectal cancer is expected to complete on July 1, 2030. The study, sponsored by M.D. Anderson Cancer Center, will assess efficacy by objective response rate and safety across three patient cohorts. Ivonescimab is being developed as a potential immunotherapy for treatment-refractory colorectal cancer. Enrollment is planned for 90 participants.
trial completion